AAPL   382.52 (+0.30%)
MSFT   213.63 (+0.38%)
FB   243.68 (+0.04%)
AMZN   3,157.22 (+2.47%)
CGC   16.05 (-1.71%)
BABA   261.68 (+1.55%)
GE   6.64 (-3.35%)
TSLA   1,397.97 (+2.35%)
AMD   56.98 (+6.64%)
T   29.64 (-2.69%)
ACB   11.65 (-4.19%)
F   5.87 (-3.61%)
GILD   74.58 (-1.36%)
DIS   116.34 (-0.27%)
NFLX   507.31 (+0.90%)
BA   173.71 (-3.54%)
AAPL   382.52 (+0.30%)
MSFT   213.63 (+0.38%)
FB   243.68 (+0.04%)
AMZN   3,157.22 (+2.47%)
CGC   16.05 (-1.71%)
BABA   261.68 (+1.55%)
GE   6.64 (-3.35%)
TSLA   1,397.97 (+2.35%)
AMD   56.98 (+6.64%)
T   29.64 (-2.69%)
ACB   11.65 (-4.19%)
F   5.87 (-3.61%)
GILD   74.58 (-1.36%)
DIS   116.34 (-0.27%)
NFLX   507.31 (+0.90%)
BA   173.71 (-3.54%)
AAPL   382.52 (+0.30%)
MSFT   213.63 (+0.38%)
FB   243.68 (+0.04%)
AMZN   3,157.22 (+2.47%)
CGC   16.05 (-1.71%)
BABA   261.68 (+1.55%)
GE   6.64 (-3.35%)
TSLA   1,397.97 (+2.35%)
AMD   56.98 (+6.64%)
T   29.64 (-2.69%)
ACB   11.65 (-4.19%)
F   5.87 (-3.61%)
GILD   74.58 (-1.36%)
DIS   116.34 (-0.27%)
NFLX   507.31 (+0.90%)
BA   173.71 (-3.54%)
AAPL   382.52 (+0.30%)
MSFT   213.63 (+0.38%)
FB   243.68 (+0.04%)
AMZN   3,157.22 (+2.47%)
CGC   16.05 (-1.71%)
BABA   261.68 (+1.55%)
GE   6.64 (-3.35%)
TSLA   1,397.97 (+2.35%)
AMD   56.98 (+6.64%)
T   29.64 (-2.69%)
ACB   11.65 (-4.19%)
F   5.87 (-3.61%)
GILD   74.58 (-1.36%)
DIS   116.34 (-0.27%)
NFLX   507.31 (+0.90%)
BA   173.71 (-3.54%)
Log in

NASDAQ:CRTXCortexyme Stock Price, Forecast & News

$45.11
-2.12 (-4.49 %)
(As of 07/9/2020 02:56 PM ET)
Add
Compare
Today's Range
$44.73
Now: $45.11
$47.75
50-Day Range
$41.47
MA: $47.93
$56.48
52-Week Range
$19.35
Now: $45.11
$73.84
Volume2,467 shs
Average Volume147,067 shs
Market Capitalization$1.33 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.79
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.99 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:CRTX
CUSIP21924P10
Phone415-910-5717

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.30 per share

Profitability

Net Income$-36,980,000.00

Miscellaneous

Employees16
Market Cap$1.33 billion
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable

Receive CRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Cortexyme (NASDAQ:CRTX) Frequently Asked Questions

How has Cortexyme's stock been impacted by COVID-19 (Coronavirus)?

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRTX stock has increased by 21.9% and is now trading at $45.11. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cortexyme?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cortexyme.

When is Cortexyme's next earnings date?

Cortexyme is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Cortexyme.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) released its quarterly earnings results on Tuesday, May, 12th. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.16. View Cortexyme's earnings history.

What price target have analysts set for CRTX?

3 equities research analysts have issued 1-year price targets for Cortexyme's stock. Their forecasts range from $59.00 to $76.00. On average, they expect Cortexyme's stock price to reach $68.33 in the next twelve months. This suggests a possible upside of 51.5% from the stock's current price. View analysts' price targets for Cortexyme.

Has Cortexyme been receiving favorable news coverage?

Headlines about CRTX stock have been trending negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cortexyme earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Cortexyme.

Are investors shorting Cortexyme?

Cortexyme saw a decline in short interest in June. As of June 30th, there was short interest totaling 1,510,000 shares, a decline of 13.2% from the June 15th total of 1,740,000 shares. Based on an average daily volume of 149,000 shares, the short-interest ratio is presently 10.1 days. Approximately 12.6% of the company's stock are sold short. View Cortexyme's Current Options Chain.

Who are some of Cortexyme's key competitors?

What other stocks do shareholders of Cortexyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include Honeywell International (HON), AT&T (T), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Verizon Communications (VZ), Cisco Systems (CSCO), CVS Health (CVS), Thermo Fisher Scientific (TMO) and Home Depot (HD).

Who are Cortexyme's key executives?

Cortexyme's management team includes the following people:
  • Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 45)
  • Mr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 63)
  • Ms. Kristen Gafric, Co-Founder, Sr. VP of Legal & Admin. and Sec. (Age 43)
  • Mr. Christopher P. Lowe, CFO & Treasurer (Age 48)
  • Dr. Michael J. Detke, Chief Medical Officer (Age 52)

When did Cortexyme IPO?

(CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

How do I buy shares of Cortexyme?

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $45.11.

How big of a company is Cortexyme?

Cortexyme has a market capitalization of $1.33 billion. The biopharmaceutical company earns $-36,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cortexyme employs 16 workers across the globe.

What is Cortexyme's official website?

The official website for Cortexyme is www.cortexyme.com.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.